SILO Pharma Inc Dossier
Qualitative Analysis
Business overview
Silo Pharma, Inc. (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions. The company's primary therapeutic focus spans post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system (CNS) diseases such as Alzheimer's disease and multiple sclerosis. Silo Pharma utilizes licensed intellectual property and technology from leading academic institutions and research partners to develop novel formulations and drug delivery systems. Its lead product candidate, SPC-15, is an intranasal prophylactic treatment targeting PTSD and anxiety. Additionally, the company is developing SP-26, a time-release ketamine-loaded subcutaneous implant for fibromyalgia and chronic pain relief. Alongside its clinical pipeline, Silo Pharma maintains a unique digital assets treasury strategy, participating in the staking of cryptocurrencies and tokenized real-world assets to generate yield.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury (TBI) and associated neuropsychiatric conditions, aligning with federal actions to accelerate mental health innovation using psychedelic medicines. The company filed a provisional patent application titled 'Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine'.
Expected impact: Aims to target an unmet medical need in a TBI therapeutics market projected to reach $6 billion by 2032.
A corporate treasury diversification strategy launched to participate in the growth of digital assets and strengthen capital resources. The strategy combines staking for yield with a hedged overlay to reduce volatility.
Expected impact: Aims to create long-term, sustainable stockholder value through asset diversification and a stronger capital foundation to fund drug development.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To diversify operations into AI technology as a second line of business, establishing a dedicated AI subsidiary to build new revenue streams from autonomous AI agents while advancing the core biopharmaceutical pipeline.
Financial impact: Paid via the issuance of 2,100,000 shares of common stock, preserving cash reserves.
Strategic Partnerships
Allucent was selected to support final preparations and the planned submission of the Investigational New Drug (IND) application to the FDA, and to conduct Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trials for SPC-15.
Terms: Includes proposed payment conditions such as upfront fees and pass-through costs outlined in a letter of intent.
To conduct a drug-device study of the formulation-specific microchip-based soft mist nasal spray system used for delivering lead asset SPC-15 directly to the brain.